<DOC>
	<DOCNO>NCT01348503</DOCNO>
	<brief_summary>The purpose study evaluate combination Revlimid速 ( lenalidomide ) Nexavar速 ( sorafenib ) treatment hepatocellular carcinoma ca n't cure surgery .</brief_summary>
	<brief_title>Lenalidomide Combination With Fixed Dose Sorafenib Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Clinical pathological diagnosis unresectable hepatocellular carcinoma ( HCC ) base radiologic criterion , elevate alpha fetoprotein and/or tissue biopsy All previous cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 28 day prior treatment study ChildPugh Liver Function Class A/B9 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 study entry Laboratory test result within protocolspecific range Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . All study participant must register mandatory RevAssist速 program , willing able comply requirement RevAssist速 ( Revlimid available restricted distribution program call `` RevAssist . '' ) Females childbearing potential must two negative pregnancy test start lenalidomide must agree use two method birth control submit pregnancy test throughout study . Able take aspirin daily prophylactic anticoagulation Age &gt; 18 year time signing informed consent form Life expectancy least 30 day No serious medical condition , laboratory abnormality , psychiatric illness ( include evidence hepatic encephalopathy ) would prevent subject signing informed consent form No pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) No patient undergone surgical resection receive chemotherapy , percutaneous ethanol injection , radiation therapy chemoembolization within 30 day prior commencement study No condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study No use experimental drug therapy within 28 day baseline No known hypersensitivity thalidomide Patients develop erythema nodosum characterize desquamating rash take thalidomide similar drug exclude No prior use lenalidomide No concurrent use anticancer agent treatments No known positivity HIV infectious hepatitis , type B8/9 C No active infection control effectively antimicrobial antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>